Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination with Pembrolizumab (MK-3475) in Subjects with Advanced Hepatocellular Carcinoma

Next Previous
Trial Profile

An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination with Pembrolizumab (MK-3475) in Subjects with Advanced Hepatocellular Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GNOS PV02 (Primary) ; Pembrolizumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Geneos Therapeutics

Most Recent Events

  • 31 Jan 2025 Planned End Date changed from 1 Jun 2025 to 29 Nov 2028.
  • 31 Jan 2025 Status changed to active, no longer recruiting.
  • 29 Jan 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top